New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k a year

The newly approved Alzheimer’s treatment Kisunla (donanemab), which can slow disease progression, will not be subsidized by the Australian government, leaving patients with annual costs between $40,000 and $80,000. Despite its potential to enhance independence and reduce care costs, the Pharmaceutical Benefits Advisory Committee has rejected its inclusion in the Pharmaceutical Benefits Scheme.